Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII

Joseph E. Addiego(Hemophilia Center of Western Pennsylvania), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), C F Abildgaard(University of California, Davis), Jeanne M. Lusher(Science Factory), Carol K. Kasper(University of Southern California), M W Hilgartner, Bertil Glader(Stanford University)
The Lancet
August 1, 1993
10.1016/0140-6736(93)91593-b
Cited by 166

Related Papers

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.
|PubMed|2001|803
Definitions in Hemophilia
|Thrombosis and Haemostasis|2001|772
A longitudinal study of orthopaedic outcomes for severe factor‐VIII‐deficient haemophiliacs
|Journal of Internal Medicine|1994|613
A More Uniform Measurement of Factor VIII Inhibitors
|Thrombosis and Haemostasis|1975|587